ACTRN12611001245987尚未招募4 期
Efficacy and safety of artemether-lumefantrine and artesunate-mefloquine for the treatment of uncomplicated falciparum malaria, and chloroquine for vivax malaria in Mu-se Township, Northern Shan State and Kalay-Ta-mu townships, Sagaing Region, Myanmar
Department of Medical Research (Upper Myanmar)0 个研究点目标入组 480 人开始时间: 2011年12月6日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 6 Years 至 60 Years(—)
- 性别
- All
入选标准
- •*age between 6 years inclusive and above except females aged 12-17 year old inclusive;
- •*mono-infection with P. falciparum detected by microscopy (parasitaemia of 500-100,000/micro l asexual forms) or P. vivax detected by microscopy (parasitaemia > 250/micro literl asexual forms);
- •*presence of axillary equal to or more than 37.5 degrees centigrade or history of fever during the past 24 hours;
- •*ability to swallow oral medication;
- •*ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
- •*informed consent from the patient or from a parent or guardian in the case of children.
排除标准
- •*presence of signs of severe falciparum malaria according to the definitions of World Health Organisation (WHO);
- •*mixed or mono-infection with another Plasmodium species detected by microscopy;
- •*presence of severe malnutrition (defined as a child whose growth standard is below 3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference below 110 mm);
- •*presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, Human Immune Deficiency Virus (HIV)/Acquired Immune Deficiency Syndrom (AIDS);
- •*regular medication, which may interfere with antimalarial pharmacokinetics;
- •*history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s); and
- •*a positive pregnancy test or breastfeeding;
- •*unable to or unwilling to take a pregnancy test or contraceptives.
研究者
相似试验
已完成
4 期
Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum in Dolisie, Republic of CongoInfection - Studies of infection and infectious agentsMalariaACTRN12616001422415Ministry of Health and Population176
尚未招募
4 期
Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Ouesso,MalariaPACTR201905606150545Health Ministry of Congo176
已完成
不适用
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria, and chloroquine for P.vivax in Kyaing Tone (Eastern Shan State)Infection - Other infectious diseasesmalariaACTRN12610000881033Clinical Research Unit (Malaria), Ministry of Defense160
已完成
不适用
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria, and chloroquine for P.vivax in Budethaung (Rakhine), Thanphyuzayat (Mon State), and Kawthaung (Tanintharyi Division)Infection - Other infectious diseasesMalariaACTRN12610000882022Department of Medical Research (Lower Myanmar)160
已完成
不适用
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria, and chloroquine for P.vivax in Myit Kyi Nar Township, Kachin State, MyanmarmalariaACTRN12610000880044Department of Medical Research (Upper Myanmar), Ministry of Health240
